Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects

• Published in: International journal of molecular sciences 2022-08, Vol.23 (16), p.8851
• Main Authors: Cincotta, Anthony H., Cersosimo, Eugenio, Alatrach, Mariam, Ezrokhi, Michael, Agyin, Christina, Adams, John, Chilton, Robert, Triplitt, Curtis, Chamarthi, Bindu, Cominos, Nicholas, DeFronzo, Ralph A.
• Format: Article
• Language: English
• Subjects: Agonists; Antioxidants; Blood; Blood glucose; Blood pressure; Bromocriptine; C-reactive protein; cardiovascular disease risk; Cardiovascular diseases; CC chemokine receptors; CCR2 protein; Circadian rhythm; Circadian rhythms; Diabetes; Diabetes mellitus (non-insulin dependent); Dopamine; Dopamine D2 receptors; Endoplasmic reticulum; Gene expression; Genes; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Immune system; Inflammation; Insulin resistance; Intercellular adhesion molecule 1; Interleukin 18; Interleukin 6; L-selectin; Leukocytes (mononuclear); Metabolism; Monocyte chemoattractant protein 1; Nervous system; NF-κB protein; Norepinephrine; Oxidative stress; Phenotypes; Plasma; Proteins; Signal transduction; sterile inflammation; Superoxide dismutase; Sympathetic nervous system; type 2 diabetes; vascular protection
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23168851

Bromocriptine-QR is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population by as yet incompletely delineated mechanisms. However, a chronic state of elevated sympathetic nervous system activity and central hypodopaminergic function has been demonstrated to potentiate an immune system pro-oxidative/pro-inflammatory condition and this immune phenotype is known to contribute significantly to the advancement of cardiovascular disease (CVD). Therefore, the possibility exists that bromocriptine-QR therapy may reduce adverse cardiovascular events in type 2 diabetes subjects via attenuation of this underlying chronic pro-oxidative/pro-inflammatory state. The present study was undertaken to assess the impact of bromocriptine-QR on a wide range of immune pro-oxidative/pro-inflammatory biochemical pathways and genes known to be operative in the genesis and progression of CVD. Inflammatory peripheral blood mononuclear cell biology is both a significant contributor to cardiovascular disease and also a marker of the body’s systemic pro-inflammatory status. Therefore, this study investigated the effects of 4-month circadian-timed (within 2 h of waking in the morning) bromocriptine-QR therapy (3.2 mg/day) in type 2 diabetes subjects whose glycemia was not optimally controlled on the glucagon-like peptide 1 receptor agonist on (i) gene expression status (via qPCR) of a wide array of mononuclear cell pro-oxidative/pro-inflammatory genes known to participate in the genesis and progression of CVD (OXR1, NRF2, NQO1, SOD1, SOD2, CAT, GSR, GPX1, GPX4, GCH1, HMOX1, BiP, EIF2α, ATF4, PERK, XBP1, ATF6, CHOP, GSK3β, NFkB, TXNIP, PIN1, BECN1, TLR2, TLR4, TLR10, MAPK8, NLRP3, CCR2, GCR, L-selectin, VCAM1, ICAM1) and (ii) humoral measures of sympathetic tone (norepinephrine and normetanephrine), whole-body oxidative stress (nitrotyrosine, TBARS), and pro-inflammatory factors (IL-1β, IL-6, IL-18, MCP-1, prolactin, C-reactive protein [CRP]). Relative to pre-treatment status, 4 months of bromocriptine-QR therapy resulted in significant reductions of mRNA levels in PBMC endoplasmic reticulum stress-unfolded protein response effectors [GRP78/BiP (34%), EIF2α (32%), ATF4 (29%), XBP1 (25%), PIN1 (14%), BECN1 (23%)], oxidative stress response proteins [OXR1 (31%), NRF2 (32%), NQO1 (39%), SOD1 (52%), CAT (26%), GPX1 (33%), GPX4 (31%), GCH1 (30%), HMOX1 (40%)],